HorStem is the first registered veterinary medicine based on mesenchymal stem cells obtained from the umbilical cord of horses. Stem cells reduce lameness in horses with mild to moderate degenerative joint disease (OA).
It is a ready-to-use, sterile, injectable suspension for intra-articular use in horses. Each vial contains 15 million active stem cells, more than enough to achieve the minimum effective dose in the joint regardless of the degree of inflammation or the patient's immune system status.
How does HorStem work?
The mechanism of action of HorStem is illustrated in the figure on the right. Mesenchymal stem cells are activated in the synovium by inflammatory cytokines. In response, they secrete anti-inflammatory cytokines such as Prostaglandin E2 (PGE2).
While PGE2 is primarily known for its pro-inflammatory effects, it also plays a crucial role in regulating inflammation. It is one of the major immunomodulatory cytokines in the body.
Expansion adds new countries to Grovet's existing PulseVet distribution coverage and enables launch of the TRUFORMA® equine platform in Europe
ANN ARBOR, MI / ACCESSWIRE / October 3, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the expansion of its distribution partnership in Europe with Grovet, a leading equine-focused veterinary distributor.
The terms of the updated agreement offer Grovet equine distribution rights for Zomedica's equine PulseVet® and TRUFORMA product platforms throughout most of Europe. Grovet will exclusively distribute these equine products in 27 countries, including Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden,
